I'll joining updates you our programs. several Thank update our on Jennifer. for pipeline updates in you, several programs on for call. guidance us our clinical Today, financial with pipeline afternoon thank and will XXXX. on everyone today's our we provide Good start and
time, several July, sent the recall general the issued advisory FDA a NKTR-XXX postponing opioid the be stated And analgesic advice committee to letter us. you which product-specific in First including at letter meetings. the had would that as FDA was sponsors will
they're advisory currently are schedule moving we're today informed forward us advisory pleased we they recently product-specific an next months. that expect us committee schedule and for based meeting the also working the conference occur report in will FDA agency meetings this that to now told While actively that to several which committee NKTR-XXX, again, to the upon
number once able once address the important program. our Journal in to it potential We've the of X pain. recently country. announce Phase our our in is in So published manuscripts a the supporting NKTR-XXX first June that molecule block long-term abuse the the a in July We in Federal in the our and significant believe data decades opioid as an in we'll and new the study the September Pain it well study plagues Medicine designed detail published published is as that respectively, forward step to which this results be has were date and as human data results, published potential published the safety that efficacy help to were be opioid This results that building includes crisis register. journal
collaborate to the a discussion meeting continue team. advisory to forward look at the with committee We and scientific FDA Rescheduled
Our wholly-owned its launch preparing Biopharma subsidiary upon to in is NKTR-XXX Inheris potential approval.
into commercial head and launch spending approval of we potential the As FDA Inheris gaiting prior is carefully to XXXX NKTR-XXX. its
NKTR-XXX. structure in launch the with more partners the distribution support of a and are finalizing process capital in to capital We for order one potential or activities
in on over three conditions. this disease last our on pathway and IL-X program Next autoimmune activates that under like great Lilly and the NKTR-XXX progress have separate and to specifically cells. T regulatory briefly NKTR-XXX is update the Nektar made and agonist I'd clinic quarter you now expands Eli in evaluation
cells. their NKTR-XXX for stimulates a of opportunity medicine that T a recent on regulatory results is expansion As preferentially first-in-class call, Lilly stated quarterly potential
study dose We this first study which lupus a by Xb medical then from plan are currently data patients, in ascending in where start dose-ranging the submit end plans of at we in in Xb study multiple upcoming We the is Phase studying to of half XXXX. NKTR-XXX the in lupus year. to an a complete to expected meeting Phase XXXX,
While we atopic psoriasis additional to program Phase plan Xb to X add and dermatitis also they initiated in in an XXXX. recently studies indication development Phase autoimmune and the
College cells dose our first-in-human conference NKTR-XXX know demonstrated you As plan of that which We June T very study data dose-dependent excited American to of at robust we in at Rheumatology without indications. and T about healthy mechanistic inflammatory and XXXX cells. Lilly volunteers fashion weekend this expansion presented to and therapeutic and for additional become of study this Atlanta. first-in-class regulatory its multiple single NKTR-XXX EULAR expansion the in data ascending meeting the in autoimmune a pharmacodynamic from achieved conventional are Nektar the potential present
IL-XX Moving program. on to agonist our NKTR-XXX,
a non-Hodgkin's to on lymphoma we excited evaluate our first will This that patients antibody in will are of ADCC monotherapy in as Jonathan cytotoxicity in report talk the quarter NKTR-XXX moment. a then clinical the myeloma. to and We combine targeted mechanism. multiple recently that trial antibody-dependent initiated about first-in-human through more work with cell-mediated safety or program an relapsed/refractory expand trial study with drugs this this
natural therapies promotes many are Mechanism. utilize strongly successfully to significant activation -- we about expansion that the Nektar potentials cells, ADCC the and excited of As killer as its with combine IL-XX survival
the NKTR-XXX is we NKTR-XXX portfolio. we with virology. therapies have nonhuman oncology know primate agents of Gilead combination with a for they different their their ongoing various preclinical evaluating currently portfolio. you several our and collaboration number NKTR-XXX in preclinical a with models in place And evaluating in in antiviral in had agent Gilead Janssen are in collaboration As for with
and mechanism antivirals. immune IL-XX As on T make potentially other effect with prolifer agonist NKTR-XXXs memory cells an combine compelling cells it to
data advancement are We and program. the our expect to with our from these IL-XX in preclinical collaborations first pleased have of XXXX
to are have constant ensures for ineligible in been manufacturing of differences we one in currently program have discovered date, in not neither to in put first-line BMS comprehensive first-line a assist BMS, the lots our used the one trials. and ensure implemented these one and in variances two have in Now three scale produced a last to two with working XX the respect strategy development early to registrational place together ongoing carcinoma. control I'd combination these in again. control will of like manufacturing were melanoma, review two any we quality ongoing cell urothelial very move In the is To and we that The registrational bempeg occur registrational first-line into from metastatic cancer, lots reiterate program. studies that commercial produced metastatic on We renal with nivo, of lots Bempeg. to bempeg of for quarter, with in the trial also
and joint that the commercialization the discussions know are the we collaboration new balance of patients. developing we highly of having to I mechanism our has plan next in to We're with in interested progressing many so for can how bempeg highly BMS. preparing to finalize bring reiterated are us steps ongoing you development BMS this with BMS future with that and are they committed immuno-oncology to
cancer, BMS first-line in a include non-small with focusing and develop trials. registrational are on includes, to to urothelial first-line next renal and ongoing This cancer strategy set cell bempeg are metastatic carcinoma. system We being eligible currently registrational cell currently nivolumab BMS metastatic lung six trials trials key with in The first-line melanoma, five planned. the of
companies are joint end plan the this working in development to collaboratively this year. Both order by finalize of
care evaluating the study non-small emerged In study cancer is lung with chemotherapy design in will as standard a patients addition, moment. Bempeg Jonathan with across with PD-LX in you first is as of the or has And discuss first-line now study line cancer. cell non-small expression cell without all know of our populations. PROPEL This on actively the more Merck's pembrolizumab. lung enrolling pembro
with BMS additional We are other the of plan indications pursuing collaborators. development joint partnership outside in
collaborations For with in other example, Bempeg ongoing and one include or neck Avelumab Talazoparib several and clinical collaborations prostate cancer in and avelumab indications. These cancer with we Pfizer with head Enzalutamide. have of
neoantigen avelumab in checkpoint neck cancer. in with – vaccibody Bioxcel Bioxcel's combination cancer Therapeutics vaccines inhibitor the of Pfizer's with in with another and pancreatic multiple head and with with One with and vaccibody’s collaboration one inhibitors DPP combination personalized in
Nektar melanoma profile in breakthrough high its unique doublet of in year Nivo as Bempeg standard of complete Of plus to granted August and this the indication well. of the a other this and there therapy were that as is this rate designation and indications of a response compared to in course, basis very care. in of on pleased expand BMS first-line potential was doublet significant, a both possibility melanoma is The metastatic
as endpoint ORR QX data in population first-line Our trial continuing could melanoma available as next be Phase early the in is the for year. X study this first to of enroll and metastatic
a PFS the Dr. will Adi metastatic an PIVOT-XX XX-month As a depth reduction cohort. know this this of lesions achieving percentage with and time include study, we of of of presentation you update study for this weekend on it in SITC about response will XXX% PIVOT-XX excited cohort the coming patients the Diab At first the first-line We're patients for present with of target from melanoma at large presentation saw patients cohort follow-up. an responses. in a complete significant very melanoma the and of
the include a.m. of SITC host a a with presentation oral X:XX view of and investors webcast and on Dr. of and The will hope you'll us attend from also can’t in Time will join webcast this a those We Eastern be who data. at data morning for Sunday will the that we held representation for Diab you person.
Jonathan discussion. the call that, With over for hand to clinical like to a I'd brief
